arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

EXAGEN INC.

XGN
$6.87 ▲ +0.26 (+3.93%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
9 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

EXAGEN INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $148.1M
Dividend Yield
Revenue Growth 19.7%
Op. Margin -21.1%
ROIC -27.5%
FCF / Share $-0.66
Trailing P/E
Price / Book 9.0x
FCF Yield
Debt / Equity 1.31
info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$66.58M
↑ +19.7%
Net Income Profit after all expenses
$-19.95M
↓ -32.0%
Operating Margin Operating profit as % of sales
-21.1%
↑ +13.8% 10th
FCF / Share Free cash flow per share
$-0.66
↑ +12.7%
Long-Term Debt Long-term obligations
$22.91M
↑ +13.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
9
Returns
7
Financial Health
29
Cash Quality
49

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters